RIBOLIFE-B (06938) announced that RBD5044 injection, independently developed by the group, has received implied approval from China's National Medical Products Administration for a Phase II clinical trial. RBD5044 is an siRNA drug targeting APOC3. APOC3 is a protein synthesized almost exclusively in the liver and plays a critical role in lipid metabolism. RBD5044 has the potential to address complications associated with hypertriglyceridemia, positioning it as a therapeutic option for managing dyslipidemia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments